Q3 Earnings Estimate for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of $1.57 per share for the quarter. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2025 earnings at $0.91 EPS and FY2029 earnings at $5.88 EPS.

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Price Performance

Sanofi stock opened at $52.97 on Wednesday. The stock’s 50 day moving average price is $48.90 and its two-hundred day moving average price is $52.22. The stock has a market capitalization of $134.43 billion, a price-to-earnings ratio of 27.03, a PEG ratio of 1.19 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC increased its holdings in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after buying an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC lifted its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.